Area of research
Neurology · Cancer Research
Research interest
Research interests include Neuroblastoma Research and Treatments, Cancer, Hypoxia, and Metabolism, Glioma Diagnosis and Treatment, and Immune cells in cancer.
Abstract 7814: Ganglioside targeting: Exerting sweet revenge on neuroblastoma
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.
Supplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.
Phase I Study of <sup>131</sup> I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma.
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Data from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Data 1 from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
Supplementary Figures from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells.
ALK upregulates POSTN and WNT signaling to drive neuroblastoma
Figure S1 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Figure S5 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Supplementary Table S2 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Supplementary Table S4 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Data from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Figure S3 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Figure S2 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Figure S6 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
Supplementary Table S1 from Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells